Helping emergency doctors make faster decisions with AI

Using Australian-developed artificial intelligence to improve emergency care.

Helping emergency doctors make faster decisions with AI

Using Australian-developed artificial intelligence to improve emergency care.
Read Transcript

The challenge

Emergency departments are under increasing pressure, with overcrowding becoming one of the biggest challenges facing the NSW health system. Doctors and nurses often need to make complex decisions about the most appropriate care for each patient, all while working under significant time pressure. Better tools to support these decisions could help patients receive the right care sooner, while improving patient flow and easing pressure on busy emergency departments.

The research

Researchers at the RPA Green Light Institute have developed The Sydney Triage to Admission Risk Tool with Artificial Intelligence (START-AI), a world-first Australian artificial intelligence tool designed to help clinicians predict whether a patient is likely to require hospital admission or can be safely discharged. Building on more than a decade of research, START-AI combines advanced artificial intelligence with clinician expertise to analyse routinely collected health information and provide real-time decision support at the bedside. 

Rather than replacing clinical judgement, START-AI is designed to support clinicians by providing additional information to help them make faster, more informed decisions. The research team is now working with NSW Health, emergency departments across metropolitan and regional NSW, and digital health leaders to implement and evaluate START-AI in real-world clinical settings.

The role of philanthropy

Funding from Hearts & Minds has helped strengthen the research capability, innovation infrastructure and collaborative partnerships needed to develop and evaluate innovative approaches to emergency care. This support has enabled the RPA Green Light Institute to generate the evidence, research publications and translational expertise required to advance START-AI from an innovative research concept towards real-world implementation across the NSW health system.


Looking ahead

The original Sydney Triage to Admission Risk Tool has already been integrated into NSW Health's Patient Flow Portal, demonstrating how Australian research can be successfully translated into everyday clinical practice. By building on this foundation, START-AI has the potential to improve the accuracy of admission decisions, reduce emergency department delays and help more patients receive timely, appropriate care.


If successfully implemented, the project could establish NSW as a global leader in AI-enabled emergency care while creating a framework for the safe introduction of artificial intelligence into public hospitals, improving care for thousands of patients each year.

Funding support from Hearts & Minds, as nominated by Regal Funds Management. This content was last updated in July 2026. For further information, visit RPA Green Light Institute for Emergency Care.

The challenge

Emergency departments are under increasing pressure, with overcrowding becoming one of the biggest challenges facing the NSW health system. Doctors and nurses often need to make complex decisions about the most appropriate care for each patient, all while working under significant time pressure. Better tools to support these decisions could help patients receive the right care sooner, while improving patient flow and easing pressure on busy emergency departments.

The research

Researchers at the RPA Green Light Institute have developed The Sydney Triage to Admission Risk Tool with Artificial Intelligence (START-AI), a world-first Australian artificial intelligence tool designed to help clinicians predict whether a patient is likely to require hospital admission or can be safely discharged. Building on more than a decade of research, START-AI combines advanced artificial intelligence with clinician expertise to analyse routinely collected health information and provide real-time decision support at the bedside. 

Rather than replacing clinical judgement, START-AI is designed to support clinicians by providing additional information to help them make faster, more informed decisions. The research team is now working with NSW Health, emergency departments across metropolitan and regional NSW, and digital health leaders to implement and evaluate START-AI in real-world clinical settings.

The role of philanthropy

Funding from Hearts & Minds has helped strengthen the research capability, innovation infrastructure and collaborative partnerships needed to develop and evaluate innovative approaches to emergency care. This support has enabled the RPA Green Light Institute to generate the evidence, research publications and translational expertise required to advance START-AI from an innovative research concept towards real-world implementation across the NSW health system.


Looking ahead

The original Sydney Triage to Admission Risk Tool has already been integrated into NSW Health's Patient Flow Portal, demonstrating how Australian research can be successfully translated into everyday clinical practice. By building on this foundation, START-AI has the potential to improve the accuracy of admission decisions, reduce emergency department delays and help more patients receive timely, appropriate care.


If successfully implemented, the project could establish NSW as a global leader in AI-enabled emergency care while creating a framework for the safe introduction of artificial intelligence into public hospitals, improving care for thousands of patients each year.

Funding support from Hearts & Minds, as nominated by Regal Funds Management. This content was last updated in July 2026. For further information, visit RPA Green Light Institute for Emergency Care.

Disclaimer: This material has been prepared by Hearts & Minds, published on . HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Picture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt CallPicture: A/Prof Melissa Call & Prof Matt Call
July 1, 2026

Next generation CAR T-cell therapy for cancer

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.

Read More
Picture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale Cohen
July 1, 2026

Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
November 15, 2024

Professor Alex Brown in conversation with Professor Jason Kovacic

At the 2024 Sohn Hearts & Minds Conference, we heard from Professor Alex Brown in conversation with Professor Jason Kovacic about Indigenous heart health and genomics.

Read More

A/Professor Tim Sargeant | 2024 Sohn Hearts & Minds Conference

Associate Professor Tim Sargeant has been at SAHMRI (South Australian Health and Medical Research Institute) in Adelaide where he studies the role of lysosomes in Alzheimer’s disease.

Read More
July 1, 2026

Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Read More
Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.
July 1, 2026

A new approach to Parkinson’s Disease

Exploring nerve stimulation as a potential treatment.

Read More
Dr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds Conference
July 1, 2026

Revealing what drives PSP

Mapping the biological changes behind progressive supranuclear palsy in the brain.

Read More
Picture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer Snaith
July 1, 2026

Advancing treatment options for type 1 diabetes

Improving blood glucose and reducing insulin needs.

Read More
Picture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish KingPicture: Dr Hamish King
July 1, 2026

Solving the genetic causes of autoimmune diseases

Mapping hundreds of risk markers to better understand how these diseases develop and progress

Read More
July 1, 2026

The Future of Pain Management

Enhancing healthcare professionals' ability to deliver better pain management, now and into the future.

Read More
July 1, 2026

Harnessing the power of stem cell technology

Developing cell therapies for patients with blood diseases

Read More
Picture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki NegishiPicture: Professor Kazuaki Negishi
July 1, 2026

Protecting the heart when every minute matters

Investigating a new treatment to reduce heart damage after heart attacks

Read More
Picture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio VittorioPicture: Associate Professor Orazio Vittorio
July 1, 2026

Targeting the drivers of cancer growth

Exploring how extrachromosomal DNA (ecDNA) drives cancer growth, spread and treatment resistance.

Read More
July 1, 2026

Improving the diagnosis of muscle disorders using advanced genetic testing

Focused on improving the efficiency and accuracy of diagnosing muscle disorders.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.